Wang Biyun, Li Xiao-Qiu, Ma Xuejun, Hong Xiaonan, Lu Hongfen, Guo Ye
Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, Fudan University, Shanghai, China.
Am J Hematol. 2008 Oct;83(10):795-9. doi: 10.1002/ajh.21256.
Overexpression of P-glycoprotein (P-gp) has been identified by a variety of methods in NK cells and NK malignancies. The aim of this study was to determine the clinical significance of P-gp in previously untreated extranodal NK/T-cell lymphoma, nasal type. Tumor specimens from 30 patients initially treated with CHOP or CHOP-based chemotherapy were examined by immunohistochemistry using JSB-1, a monoclonal antibody recognizing the intracellular epitope of P-gp molecule. Twenty cases (67%) were positive for P-gp expression. The complete response rate achieved in P-gp positive patients was significantly lower than in P-gp negative ones (20% vs. 60%, P = 0.045). With a median follow-up of 25 months, the 2-year progression-free survival (PFS) and overall survival (OS) rates for all patients were 66 and 69%, respectively. Compared with both PFS and OS rates of P-gp positive patients, those of P-gp negative patients showed a trend of benefit that did not reach statistical significance for borderline P values (PFS: 90% vs. 54%, P = 0.1057; OS: 90% vs. 61%, P = 0.2028). Our results suggest that P-gp expression is related with poor treatment outcomes of extranodal NK/T-cell lymphoma, nasal type.
通过多种方法已在自然杀伤细胞（NK细胞）和NK细胞恶性肿瘤中鉴定出P-糖蛋白（P-gp）的过表达。本研究的目的是确定P-gp在先前未经治疗的鼻型结外NK/T细胞淋巴瘤中的临床意义。使用识别P-gp分子细胞内表位的单克隆抗体JSB-1，通过免疫组织化学对30例最初接受CHOP或基于CHOP的化疗的患者的肿瘤标本进行检测。20例（67%）患者P-gp表达呈阳性。P-gp阳性患者的完全缓解率显著低于P-gp阴性患者（20%对60%，P = 0.045）。中位随访25个月时，所有患者的2年无进展生存率（PFS）和总生存率（OS）分别为66%和69%。与P-gp阳性患者的PFS和OS率相比，P-gp阴性患者的PFS和OS率显示出获益趋势，但临界P值未达到统计学显著性（PFS：90%对54%，P = 0.1057；OS：90%对61%，P = 0.2028）。我们的结果表明，P-gp表达与鼻型结外NK/T细胞淋巴瘤的不良治疗结果相关。
